Prestige Consumer Healthcare Business Summary

Prestige Consumer Healthcare Inc. (PBH) operates as a leading pure-play provider of over-the-counter (OTC) healthcare products, generating revenue through the marketing, sale, and distribution of a diverse portfolio of established niche brands. The company’s business is divided into two primary segments: North American OTC Healthcare and International OTC Healthcare. Its strategy centers on acquiring under-managed brands and revitalizing them through targeted marketing and supply chain optimization, exemplified by its February 2026 vertical integration through the acquisition of Pillar5 Pharma to secure production for its Clear Eyes line. PBH competes directly with major consumer health players such as Haleon, Church & Dwight Co., and Kenvue. Within this landscape, Prestige distinguishes itself as a high-margin, cash-generative specialist that focuses on category-leading brands in underserved segments like gastrointestinal care, eye care, and pediatric health. The company is led by Chairman, President, and CEO Ron Lombardi, who has steered the firm since 2015 and previously served as its CFO, bringing a background in private equity-backed financial management from Waterbury International Holdings. Supporting him is Christine Sacco, who serves as both Chief Financial Officer and Chief Operating Officer (promoted to the dual role in January 2025), leveraging her prior experience as CFO of Boulder Brands. The executive team was further bolstered in January 2026 by the appointment of José Luis Rosado as SVP of Quality & Regulatory Affairs, a veteran of Johnson & Johnson and OraSure. Prestige is backed by a robust institutional investor base, with BlackRock, Inc. and The Vanguard Group holding significant stakes of approximately 16% and 11% respectively, while the Board of Directors includes seasoned industry leaders such as Lead Independent Director John Byom and former Kellogg executive Dr. Celeste Clark.